Ashton Thomas Private Wealth LLC Cuts Holdings in Zoetis Inc. $ZTS

Key Points

• Ashton Thomas Private Wealth LLC cut its stake in Zoetis by 73.0% in Q4, selling 22,060 shares and leaving the firm with 8,176 shares worth about $1.03 million.
• Zoetis beat Q4 estimates with $1.48 EPS and $2.39B revenue, set FY2026 guidance of $7.00–$7.10 EPS, and announced a $0.53 quarterly dividend (annualized $2.12, ~1.8% yield).
• Institutional investors own about 92.8% of Zoetis; UBS holds roughly 2.83M shares (~$355.7M), while analysts are split with a consensus rating of "Hold" and a $151.75 price target.

Ashton Thomas Private Wealth LLC reduced its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 73.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,176 shares of the company's stock after selling 22,060 shares during the quarter. Ashton Thomas Private Wealth LLC's holdings in Zoetis were worth $1,029,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Washington Capital Management Inc. raised its position in shares of Zoetis by 58.5% in the 4th quarter. Washington Capital Management Inc. now owns 4,390 shares of the company's stock worth $552,000 after buying an additional 1,620 shares during the period. Aprio Wealth Management LLC raised its position in shares of Zoetis by 49.4% in the 4th quarter. Aprio Wealth Management LLC now owns 2,868 shares of the company's stock worth $361,000 after buying an additional 948 shares during the period. Quest 10 Wealth Builders Inc. raised its position in shares of Zoetis by 4.7% in the 4th quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company's stock worth $240,000 after buying an additional 86 shares during the period. UBS Group AG raised its position in shares of Zoetis by 0.6% in the 4th quarter. UBS Group AG now owns 2,827,318 shares of the company's stock worth $355,733,000 after buying an additional 17,687 shares during the period. Finally, Teachers Retirement System of The State of Kentucky raised its position in shares of Zoetis by 127.2% in the 4th quarter. Teachers Retirement System of The State of Kentucky now owns 80,198 shares of the company's stock worth $10,091,000 after buying an additional 44,894 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $115.10 on Friday. The company has a market cap of $48.42 billion, a P/E ratio of 19.12, a PEG ratio of 1.75 and a beta of 0.98. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. Zoetis Inc. has a one year low of $112.97 and a one year high of $172.23. The business's 50-day simple moving average is $119.93 and its 200 day simple moving average is $124.79.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. The business had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company's revenue was up 3.0% on a year-over-year basis. During the same period last year, the business posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, sell-side analysts forecast that Zoetis Inc. will post 7.02 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. Zoetis's dividend payout ratio (DPR) is currently 35.22%.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ZTS. William Blair reaffirmed an "outperform" rating on shares of Zoetis in a research report on Monday, March 2nd. BTIG Research reaffirmed a "buy" rating and issued a $160.00 target price on shares of Zoetis in a research report on Thursday, February 26th. Leerink Partners reaffirmed a "market perform" rating on shares of Zoetis in a research report on Tuesday, March 10th. Bank of America increased their target price on Zoetis from $135.00 to $140.00 and gave the stock a "neutral" rating in a research report on Friday, February 13th. Finally, Citigroup initiated coverage on Zoetis in a report on Wednesday, April 15th. They issued a "buy" rating and a $145.00 price target for the company. Seven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $151.75.

Zoetis Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.